A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases-Reference-Cited by-同舟云学术

A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases

Published:2018-05-11 Issue:8 Volume:12 Page:954-962
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:

Author:

Lee Choon Kin¹,Wong Sunny H v¹,Lui Grace²,Tang Whitney¹,Tam Lai San³,Ip Margaret⁴,Hung Esther⁵,Chen Minhu⁶,Wu Justin C¹,Ng Siew C¹

Affiliation:

1. Department of Medicine and Therapeutics, Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong, China

2. Department of Medicine and Therapeutics, Division of Infectious Disease, Chinese University of Hong Kong, Hong Kong, China

3. Department of Medicine and Therapeutics, Division of Rheumatology, Chinese University of Hong Kong, Hong Kong, China

4. Department of Microbiology, Chinese University of Hong Kong, Hong Kong, China

5. Department of Radiology, Chinese University of Hong Kong, Hong Kong, China

6. Department of Gastroenterology and Hepatology, First Affliated Hospital, Sun Yat-Sen University, Guangzhou, China

Funder

Food and Health Bureau

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/12/8/954/25177505/jjy057.pdf

Reference38 articles.

1. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

2. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial;Braun;Lancet,2002

3. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis;Saag;Arthritis Rheum,2008

4. Update on latent tuberculosis infection;Hartman-Adams;Am Fam Physician,2014

5. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent;Keane;N Engl J Med,2001

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review;Revista da Sociedade Brasileira de Medicina Tropical;2024

2. Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review;Frontiers in Pharmacology;2023-01-20

3. Management and monitoring of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical management, disease monitoring, and special considerations;Journal of Gastroenterology and Hepatology;2023-01-13

4. Active tuberculosis in inflammatory bowel disease patients: a case–control study;Therapeutic Advances in Gastroenterology;2023-01

5. Interferon-γ release assay screening in biologics: safe and reliable, but not perfect;ERJ Open Research;2022-10